Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,963.00    41.50 (2.16%)
Bid:
1,962.50
Ask:
1,963.00
Spread: 0.50 (0.025%)
Market Cap: £78.69b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Issuance of Notes

23 Mar 2022 07:00

RNS Number : 6780F
GlaxoSmithKline PLC
23 March 2022
 

GlaxoSmithKline plc

Issued: 23 March 2022, London UK

 

 

 

ISSUANCE OF NOTES

 

GSK Consumer Healthcare Capital UK plc and GSK Consumer Healthcare Capital NL B.V. (together with GSK Consumer Healthcare Capital UK plc, the "EMTN Issuers") announce that, on 22 March 2022, they successfully priced the following notes (the "EMTN Notes") under the GBP 10,000,000,000 Euro Medium Term Note Programme of the EMTN Issuers:

- GBP 300,000,000 2.875% Fixed Rate Senior Notes due 2028 and GBP 400,000,000 3.375% Fixed Rate Senior Notes due 2038, each issued by GSK Consumer Healthcare Capital UK plc; and

 

- EUR 850,000,000 1.250% Fixed Rate Notes due 2026, EUR 750,000,000 1.750% Fixed Rate Senior Notes due 2030 and EUR 750,000,000 2.125% Fixed Rate Senior Notes due 2034, each issued by GSK Consumer Healthcare Capital NL B.V.

 

In addition, GSK Consumer Healthcare Capital UK plc and GSK Consumer Healthcare Capital US LLC announce that, on 21 March 2022, they successfully priced the following notes (the "144A Notes") pursuant to an Offering Memorandum dated 21 March 2022:

 

- USD 700,000,000 3.024% Callable Fixed Rate Senior Notes due 2024, USD 300,000,000 Callable Floating Rate Senior Notes due 2024, USD 2,000,000,000 3.375% Fixed Rate Senior Notes due 2027, USD 1,000,000,000 3.375% Fixed Rate Senior Notes due 2029, USD 2,000,000,000 3.625% Fixed Rate Senior Notes due 2032 and USD 1,000,000,000 4.000% Fixed Rate Senior Notes due 2052, each issued by GSK Consumer Healthcare Capital US LLC; and

 

- USD 1,750,000,000 3.125% Fixed Rate Senior Notes due 2025 issued by GSK Consumer Healthcare Capital UK plc.

The EMTN Notes and the 144A Notes (together, the "Notes") will be guaranteed by GlaxoSmithKline plc up to and excluding the Guarantee Assumption Date (as defined in the Terms and Conditions of the Notes).

 

For further information, please contact:

GlaxoSmithKline plc980 Great West RoadBrentfordMiddlesexTW8 9GSUnited Kingdom

UK Media enquiries:

David Mawdsley Simon Steel

Tim Foley

+44 (0) 20 8047 5502

+44 (0) 20 8047 5502

+44 (0) 20 8047 5502

(London)

(London)

(London)

 

 

 

 

European Analyst/Investor enquiries:

James Dodwell

Danielle Smith

+44 (0) 20 8047 2406

+44 (0) 20 8047 0932

(London)

(London)

 

 

IMPORTANT DISCLAIMER: This announcement does not constitute an offer of any securities for sale (including, without limitation, any Notes). The offer and sale of the Notes may be restricted by law in certain jurisdictions.

This document does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities in the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia) (the "United States"). The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or under the securities laws of any state of the United States, and may not be offered, sold, resold or delivered directly or indirectly, in or into the United States or to a U.S. person absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IODDDGDXXSDDGDD
Date   Source Headline
11th Jun 20263:30 pmRNSDirector/PDMR Shareholding
10th Jun 20263:30 pmRNSDirector/PDMR Shareholding
9th Jun 20265:51 pmRNSDr Hal Barron – New Directorship
9th Jun 20267:00 amRNSGSK enters agreement to acquire Nuvalent, Inc.
8th Jun 20263:00 pmRNSTransaction in Own Shares
1st Jun 20263:00 pmRNSTotal Voting Rights
1st Jun 20263:00 pmRNSTransaction in Own Shares
28th May 20269:30 amRNSPositive Phase 3 data for bepirovirsen
27th May 20263:30 pmRNSDirector/PDMR Shareholding
26th May 20263:00 pmRNSAdmission to Trading
26th May 20263:00 pmRNSTransaction in Own Shares
22nd May 202610:30 amRNSQ2 2026 Results Date Confirmed - 28 July 2026
20th May 20263:30 pmRNSDirector/PDMR Shareholding
19th May 20263:30 pmRNSDirector/PDMR Shareholding
18th May 20263:00 pmRNSTransaction in Own Shares
18th May 20267:00 amRNSJapan MHLW approves Arexvy for adults 18-49 AIR
14th May 20263:30 pmRNSDirector/PDMR Shareholding
11th May 20263:30 pmRNSDirector/PDMR Shareholding
11th May 20267:05 amRNSCollaboration with CTTQ for bepirovirsen
11th May 20267:00 amRNSGSK - final tranche of share buyback programme
6th May 20266:22 pmRNSResult of AGM
5th May 20263:30 pmRNSDirector/PDMR Shareholding
1st May 20263:00 pmRNSHolding(s) in Company
1st May 20263:00 pmRNSTotal Voting Rights
29th Apr 20263:30 pmRNSDirector/PDMR Shareholding
29th Apr 20267:00 amRNS1st Quarter Results
28th Apr 20263:30 pmRNSDirector/PDMR Shareholding
28th Apr 20267:00 amRNSBepirovirsen priority review US filing acceptance
27th Apr 202612:00 pmRNSEfimosfermin granted US/EU regulatory designations
27th Apr 20267:00 amRNSTESARO update on AnaptysBio Inc. litigation
24th Apr 20263:30 pmRNSDirector/PDMR Shareholding
23rd Apr 20267:00 amRNSTransaction in Own Shares
22nd Apr 20267:00 amRNSTransaction in Own Shares
21st Apr 20267:00 amRNSTransaction in Own Shares
20th Apr 20263:30 pmRNSDirector/PDMR Shareholding
20th Apr 20267:00 amRNSBlenrep approved in China for 2L+ multiple myeloma
20th Apr 20267:00 amRNSTransaction in Own Shares
17th Apr 20267:00 amRNSTransaction in Own Shares
16th Apr 20263:30 pmRNSDirector/PDMR Shareholding
16th Apr 20267:00 amRNSTransaction in Own Shares
15th Apr 20267:12 amRNSGSK completes acquisition of 35Pharma Inc.
15th Apr 20267:00 amRNSTransaction in Own Shares
14th Apr 20263:30 pmRNSDirector/PDMR Shareholding
14th Apr 20267:00 amRNSTransaction in Own Shares
13th Apr 20263:30 pmRNSDirector/PDMR Shareholding
13th Apr 20267:00 amRNSTransaction in Own Shares
13th Apr 20267:00 amRNSGSK presents positive data for BEHOLD 1 B7 H4 ADC
10th Apr 20263:30 pmRNSDirector/PDMR Shareholding
10th Apr 20267:00 amRNSTransaction in Own Shares
9th Apr 20263:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.